The reaffirmation of an Overweight rating and a $58 price target by a prominent analyst like Ryan Kenny from Morgan Stanley is likely to instill confidence among investors about Lazard's prospects. This endorsement could lead to a positive short-term impact on Lazard's stock price as market participants react to the analyst's optimistic outlook.